Loading stock data…
Actinium Pharmaceuticals, Inc. (ATNM)
$1.23+0.20 (+19.42%)
After Hours$1.24+0.01 (+0.81%)· Last close Sep 8
Actinium Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Actinium Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.23 with a market capitalization of $31M. Wall Street consensus targets $3.50 (4 analysts), implying a +184.6% move over the next 12 months. The stock is currently 29% below its 52-week high of $1.74, remaining 6.0% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +184.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $90,000 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.90M↑ | -$6.41M↓ | -$5.69M↑ | -$7.50M↑ | -$16.64M |
| Net Income | -$5.52M↑ | -$5.94M↓ | -$5.13M↑ | -$6.88M↑ | -$15.94M |
Peer Comparison
JNJUNHPFE
Fundamentals
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeut...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.06M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.05
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1018.71%
Volume
Today's trading volume
569,098
Recent News
Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year?
Here is how Actinium Pharmaceuticals (ATNM) and Collegium Pharmaceutical (COLL) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Alpha Cognition Inc. (ACOG) This Year?
Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Is Alpha Cognition Inc. (ACOG) Stock Outpacing Its Medical Peers This Year?
Here is how Alpha Cognition Inc. (ACOG) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Actinium: Q3 Earnings Snapshot
NEW YORK (AP) — Actinium Pharmaceuticals Inc. ATNM) on Friday reported a loss of $5.1 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 16 cents.
Sector Update: Health Care Stocks Advance Monday Afternoon
Health care stocks rose Monday afternoon, with the NYSE Health Care Index and the Health Care Select